Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 60, Issue 11, Pages 1252-1265Publisher
ELSEVIER
DOI: 10.1016/j.addr.2008.03.018
Keywords
magnetic nanoparticle; MRI; contrast agent; drug delivery; targeting; DNA; siRNA; peptide; ligand; cancer; biodistribution
Categories
Funding
- NCI NIH HHS [R01 CA119408-04, R01CA119408, R01 CA134213-02, R01 CA134213, R01 CA119408, R01CA134213] Funding Source: Medline
- NIBIB NIH HHS [R01 EB006043-02, R01 EB006043, R01EB006043] Funding Source: Medline
Ask authors/readers for more resources
Magnetic nanoparticles (MNPs) possess unique magnetic properties and the ability to function at the cellular and molecular level of biological interactions making them an attractive platform as contrast agents for magnetic resonance imaging (MRI) and as carriers for drug delivery. Recent advances in nanotechnology have improved the ability to specifically tailor the features and properties of MNPs for these biomedical applications. To better address specific clinical needs, MNPs with higher magnetic moments, non-fouling surfaces, and increased functionalities are now being developed for applications in the detection, diagnosis, and treatment of malignant tumors, cardiovascular disease, and neurological disease. Through the incorporation of highly specific targeting agents and other functional ligands, such as fluorophores and permeation enhancers, the applicability and efficacy of these MNPs have greatly increased. This review provides a background on applications of MNPs as MR imaging contrast agents and as carriers for drug delivery and an overview of the recent developments in this area of research. (c) 2008 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available